Haemonetics (HAE) | Stock Overview & Key Data
Haemonetics Performance Comparison
Stock Range
Today's Range
Low: $54.02
High: $55.12
on August 29, 2025
52 Week Range
Low: $50.68
High: $94.99
on August 12, 2025
on November 12, 2024
All-Time High: $142.11 on February 8, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.7B
EPS
3.27
P/E Ratio (TTM)
16.89
Forward P/E
10.34
P/B Ratio
3.01
PEG Ratio
-2.77
Div. Yield
N/A
ROE
18.27%
Beta
0.404
Debt to Equity
138.87
Financial Highlights
Profitability
Gross Margin
59.82%
Operating Margin
20.21%
Profit Margin
12.14%
Returns and Earnings
Return on Assets (TTM)
6.52%
Return on Equity (TTM)
18.27%
EBITDA
$351.1M
Net Income (TTM)
$163.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$27.92
Quarterly Revenue Growth (YoY)
-4.40%
Quarterly Earnings Growth (YoY)
-11.30%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Haemonetics HAE | 2.66B Mid-cap | -3.25% | -27.80% | -19.60% | -16.73% | -30.43% | -27.84% | -26.04% | -39.08% |
| Abbott Laboratories ABT | 230.89B Mega-cap | 0.05% | 3.63% | -0.14% | -3.88% | 16.94% | 17.12% | 29.42% | 27.36% |
| Boston Scientific BSX | 157.64B Large-cap | -0.63% | -0.91% | 0.96% | 1.65% | 18.04% | 28.99% | 160.56% | 154.34% |
| Globus Medical GMED | 8.32B Mid-cap | -2.00% | 13.38% | 4.04% | -23.72% | -25.13% | -15.72% | 5.18% | 10.88% |
| Bio-Rad Laboratories BIO | 7.73B Mid-cap | -1.96% | 17.93% | 30.87% | 12.34% | -8.67% | -11.69% | -37.72% | -38.48% |
| Masimo MASI | 7.73B Mid-cap | -6.00% | -12.10% | -11.00% | -25.99% | -17.12% | 18.88% | -3.16% | -34.63% |
Ownership & Short Interest
Insider Ownership
1.15%
Institutional Ownership
118.37%
Shares Short
4M
Short Ratio
4.26
Short % of Shares Outstanding
12.05%
Average 10-Day Volume
1M
Average 90-Day Volume
1M
Haemonetics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Haemonetics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is HAE's 52-week high and low?
- In the last 52 weeks, Haemonetics reached a high of $94.99 (on November 12, 2024) and a low of $50.68 (on August 12, 2025).
- What is the market cap and P/E ratio for HAE?
- Curious about Haemonetics's size and valuation? Its market capitalization stands at 2.66B. When it comes to valuation, the P/E ratio (trailing twelve months) is 16.89, and the forward P/E (looking ahead) is 10.34.
- Does HAE pay dividends? If so, what's the yield?
- As for dividends, Haemonetics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Haemonetics's main competitors or similar companies to consider before investing?
When looking at Haemonetics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT230.89B Healthcare Medical Devices 17.12% 29.42% Boston Scientific
BSX157.64B Healthcare Medical Devices 28.99% 160.56% Globus Medical
GMED8.32B Healthcare Medical Devices -15.72% 5.18% Bio-Rad Laboratories
BIO7.73B Healthcare Medical Devices -11.69% -37.72% Masimo
MASI7.73B Healthcare Medical Devices 18.88% -3.16% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Haemonetics Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Haemonetics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.27%, the Debt to Equity ratio from the most recent quarter is 138.87, and its Gross Profit Margin stands at 59.82%.
- What is the recent revenue and earnings growth for HAE?
- Looking at Haemonetics's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by -4.40%, and quarterly earnings saw a YoY growth of -11.30%.
- How much of HAE stock is held by insiders and institutions?
- Wondering who owns Haemonetics stock? Company insiders (like executives and directors) hold about 1.15% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 118.37%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.